Tim Wyant

Tim Wyant is a co-founder of Aulos and the company’s senior vice president and head of early development. He has over 20 years of biotech and pharmaceutical experience focusing on translational research bringing drugs from preclinical studies into the clinic. Previously, Tim was vice president of Immunology at Abpro, and before that senior director of Immunology at Curis, where he oversaw bringing lead assets to IND. Prior to that, he spent 14 years at Millennium Pharmaceuticals/Takeda, where he led the translational strategy for multiple antibody and small molecule drugs, overseeing pre-IND activities and first-in-human studies through regulatory filings and approval. Tim was the translational lead for Entyvio (vedolizumab) for its worldwide approvals, and the EMEA approval lead for Adcetris (brentuximab vedotin), an ADC oncology therapeutic jointly developed by Millennium/Takeda and Seattle Genetics (Seagen).

Tim received a B.S. in biology from Arizona State University and a Ph.D. in immunology from the University of Arizona and trained as a post-doctoral fellow in vaccines at the University of Maryland Center for Vaccine Development.